Pandion’s lead candidate PT101 has completed a phase 1a clinical trial backing its safety and tolerability, and is due to start a phase 1a/2b study in ulcerative colitis and a phase 2 trial in ...
Astellas Pharma is boosting its early-stage pipeline with a $45 million upfront deal to license bispecific antibodies from US biotech Pandion Therapeutics with potential in the treatment of type 1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results